The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

PARIS, France – December 17, 2025 – 10:05 pm CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on ...

ECCO 2026 Severe Infection Linked to Long-term IBD Risk Severe infections requiring hospitalization are associated with a markedly increased long-term IBD risk, with immune-related genetic variants ...

Iterative Health, a healthcare technology and services company powering the acceleration of clinical research, today announced the publication of scientific research at the 21st Congress of European ...

Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026 22 abstracts presented at ...

Breadth of Scientific Evidence: The acceptance of 1 oral presentation, 5 digital oral presentations and 16 posters reflect an expanding dataset for obefazimod, including additional efficacy, safety, ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Iterative Health, a healthcare technology and services company powering the acceleration of clinical research, today announced the publication of scientific research ...

The issuer is solely responsible for the content of this announcement. Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral ...